Efficacy of *Lycium barbarum* L. on plasma lipid concentration in adults

A protocol for systematic review and meta-analysis

Xueyuan Zeng, MD\textsuperscript{a}, Weimin Zhao, MS\textsuperscript{b}, Yunlong Xu, MD, PhD\textsuperscript{b}, Chengwei Zhang, MS\textsuperscript{a}, Junliang Wu, MS\textsuperscript{a}, Libo Xia, MD\textsuperscript{a}, Ziyue Tian, MD\textsuperscript{a}, Jixiang Ren, MD, PhD\textsuperscript{b,*}

Abstract

**Background:** Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease. *Lycium barbarum* L. are widely used as medicinal and functional food and may be particularly beneficial for patients with dyslipidemia. This systematic review protocol is designed to be used to evaluate the effects of *Lycium barbarum* L. on plasma lipid concentration through systematic reviews and meta-analysis.

**Methods:** The following electronic databases will be searched from inception to October 2021: the China National Knowledge Infrastructure, PubMed, Cochrane Library, Web of Science, and Wan-fang database. All randomized controlled trial designs evaluated the effects of *Lycium barbarum* L. on plasma concentrations of lipids will be included. Two researchers will operate literature retrieval, screening, information extraction, quality assessment, and data analysis independently. The analysis will be conducted using Rstudio software (Version 1.4.1717).

**Results:** The findings will be submitted to a peer-reviewed publication.

**Conclusion:** This study will provide practical and targeted evidence in investigating the impact of *Lycium barbarum* L. on plasma lipid concentration in adults.

**Registration number:** INPLASY2021110043

**Abbreviations:** HDL-C = high-density lipoprotein-cholesterol, LDL-C = low-density lipoprotein-cholesterol, TC = total cholesterol, TG = triglyceride.

**Keywords:** *Lycium barbarum* L., meta-analysis, plasma lipid concentration, protocol

1. Introduction

Dyslipidemia refers to a group of lipid abnormalities including elevated low-density lipoprotein cholesterol (LDL-C), hypercholesterolemia, hypertriglyceridemia, and low high-density lipoprotein cholesterol (HDL-C). Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease. Many studies have shown that lowering LDL-C levels can significantly reduce the risk of morbidity and mortality from atherosclerotic cardiovascular disease. Prevention and proper management of dyslipidemia can significantly change cardiovascular morbidity and mortality. However, the management of dyslipidemia is extremely challenging. Statins are the cornerstone of drug therapy for dyslipidemia. However, statins may cause some adverse reactions, such as elevated liver transaminase, muscle damage, elevated blood sugar, and cognitive impairment. Diet and lifestyle are one of the important causes of dyslipidemia. Diet treatment and lifestyle improvement are the basic measures to treat dyslipidemia.

In recent years, more and more natural medicines have been found to have active ingredients to improve dyslipidemia. The intervention of Chinese medicine on dyslipidemia has aroused people’s attention. Among them, Chinese wolfberry also known as *Lycium barbarum* L. or Goji berry, is widely used in the Asia-Pacific region as both medicine and food. *Lycium barbarum* L. were first used as medicinal plants about 2300 years ago. In China, it is used as traditional Chinese medicine and functional food in daily life because of its health benefits. *Lycium barbarum* L. has the effect of nourishing liver and tonifying kidney, protecting eyesight. Modern medical research shows that wolfberry has anti-aging, anti-oxidation, anti-diabetes, anti-cancer, cell protection, neuroprotection, and immunomodulatory effects. Using chromatographic techniques, the researchers...
identified a variety of chemical components, including polysaccharides, carotenoids, flavonoids, and alkaloids. *L. barbarum* polysaccharides was the most widely studied. *L. barbarum* polysaccharides has a variety of physiological effects, such as antioxidant function, antitumor activity, neuroprotection, immunomodulatory function, and other biological functions.\[13\]

In vitro and in vivo studies, *Lycium barbarum L.* exhibited lipid-lowering, antioxidant, and anti-inflammatory properties.\[16,17\] However, the results of randomized controlled trials on *Lycium barbarum L.* have been inconsistent in clinical studies. Studies have shown that taking goji berries for 45 days on a healthy diet can significantly improve lipoprotein levels in patients with metabolic syndrome.\[18\] Using standardized goji berry juice can improve neurophysiological performance, as well as overall health and well-being.\[19\] In contrast, other studies indicated that standardized goji berry juice or Wolfberry have no benefits on weight, blood pressure, and blood lipids.\[20–23\] The effect of *Lycium barbarum L.* supplementation on lipid concentration is controversial. Whether the hypolipidemic effect of Wolfberry is consistent in healthy people or clinical population is considered. Therefore, we suggest a systematic review and meta-analysis of the effects of *Lycium barbarum L.* on plasma lipid concentration.

2. Methods

2.1. Study registration

The protocol for this systematic review was registered on INPLASY (registration number INPLASY2021110043). Our review will comply with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines.\[24\]

2.2. Inclusion criteria for study selection

2.2.1. Inclusion/exclusion of articles. Trials with the following inclusion criteria will be included: applied a RCT; evaluated the effects of *Lycium barbarum L.* on plasma/serum concentrations of lipids will be included; and presented mean and standard deviation (SD) in both intervention and control groups. Due to language restrictions, we will search for articles in English and Chinese to get a more objective and a true evaluation.

2.2.2. Type of participants. Subjects aged over 18 will be included in the review. There will be no restriction on sex, ethnicity, or disease duration.

2.2.3. Type of intervention. Comparison interventions included placebo control, no therapy, exercise intervention, diet intervention, or active pharmacological treatment. Studies that administered *Lycium barbarum L.* in combination with other components will be excluded.

2.2.4. Type of comparators. Studies for the effect of *Lycium barbarum L.* on plasma lipid concentration in adults will be included. The only difference between the control and treatment groups was *Lycium barbarum L.*

2.2.5. Outcome measurements. The primary aim is to review the literature and synthesize relevant data to investigate the effects of *Lycium barbarum L.* on plasma concentrations of lipids in adults comprehensively. Variables such as the concentrations of total cholesterol (TC), triglyceride (TG), LDL-C, and HDL-C will be included.

2.3. Search strategy

The following electronic databases will be searched from inception to October 2021: the China National Knowledge Infrastructure, PubMed, Cochrane Library, Web of Science, and Wan-fang databases. The search was restricted to published studies on humans without language restriction. We used the following keywords as search terms: (“Lycium barbarum L.” OR “L. barbarum” OR “Goji” OR “lycium” OR “wolfberry”) AND (“Intervention Studies” OR “intervention” OR “controlled trial” OR “randomized” OR “randomised” OR “random” OR “randomly” OR “placebo” OR “assignment”). About other sources, we also plan to manually search for the unpublished conference articles and the bibliography of established publications. In addition, a manual search of recent reviews, meta-analyses, and original studies were also scrutinized.

2.4. Data collection and analysis

2.4.1. Selection of studies. A PRISMA flow diagram will be used to document the whole trial selection process (Fig. 1). Studies retrieved in the databases will be uploaded to the software reference manager EndNote X8 for screening. Abstracts of all articles will be screened independently by 2 reviewers based on eligibility criteria. If there is any inconsistency in the inclusion of an article, a third reviewer will be consulted independently. Retained articles will be reviewed in full.

2.4.2. Data extraction and management. The authors will follow the inclusion criteria strictly and selected RCT articles related to the topic. Data for the trials will be extracted independently by 2 review authors using a standard form. The extracted information was as follows: study characteristics (first author’s last name, year of publication, location of the study, sample size, and study design); participants’ information (gender, mean age, mean body mass index, and health status); intervention details (duration of treatment and dose); and investigated outcomes including TC, TG, LDL-C, and HDL-C.

2.4.3. Assessment of bias in the included studies. Each trial included in the review will be independently assessed by 2 reviewers for potential biases. For any disagreement, a third reviewer will help to confirm the final assessment. Original article authors will be contacted (when possible), if there are insufficient details to confidently assess the risk of bias. We will use the Cochrane collaborative tool to independently assess the risk of bias in the included studies. The Cochrane Collaboration’s tool assigns scores for following domains: random sequence generation (selection bias); allocation concealment (selection bias); blinding of participants and personnel (performance bias); blinding of outcome assessment (detection bias); incomplete outcome data (attrition bias); selective reporting (reporting bias); and other sources of bias. The risk of bias is evaluated at 3 levels, namely, low risk, high risk, high risk. A risk of bias summary table will be produced.

2.4.4. Data analysis. When the data permits, the analysis will be done using Rstudio software (Version 1.4.1717). Preintervention and postintervention means ± SDs of TC, TG, LDL-C, and HDL-C in both *Lycium barbarum L.* and control groups will be extracted. All of standard error of mean was changed to SD by multiplying standard error of mean to $\sqrt{n}$. We used the suitable formula $SD_{change} = square\ root\ ([SD_{baseline}^2 + SD_{final}^2] - (2 \times r \times SD_{baseline} \times SD_{final}))$ to calculate SD of the mean difference in studies that did not report this parameter. Correlation coefficient
will be estimated according to following formula: 
\[ r = \frac{(SD_1^2 + SD_2^2 - SD_{Change}^2)}{2SD_1 \times SD_2}. \]
The heterogeneity between the included studies will be analyzed by Cochran Q test and Higgins I^2 statistic. If there is no statistical heterogeneity between the results of each study \((P > .1, I^2 < 50\%)\), the fixed-effect model will be used for meta-analysis. If not, the source of heterogeneity will be further analyzed and the random-effect model will be used for analysis after excluding the influence of obvious clinical heterogeneity. All outcomes will be analyzed through 95% confidence intervals. If there are insufficient data to support meta-analysis, descriptive analysis will be implemented.

2.4.5. **Subgroup analysis.** Subgroup analyses will be conducted for based on gender, intervention duration, *Lycium barbarum L.* dose, and type of study population (healthy or unhealthy) when data are available.

2.4.6. **Sensitivity analysis.** Sensitivity analysis is performed when Cochran Q test and Higgins I^2 statistic show significant heterogeneity. We will eliminate each study one by one to identify literature that has apparent impact on the original effects. The reasons for the obvious heterogeneity of the literature will be scrutinized from the aspects of sample size, study quality, and statistical methods.

2.4.7. **Evidence assessed.** The evidence quality will be evaluated by the recommended grading method of the GRADE system, and the evidence quality is divided into 4 levels, namely A (high quality), B (medium quality), C (low quality), and D (very low quality).

2.4.8. **Assessment of reporting biases.** If more than 10 articles will be included, a funnel plot would be used to demonstrate publication bias by its symmetry.

2.4.9. **Ethics and dissemination.** Because this study does not involve private patient information, no ethical review is required. The results of this systematic review and meta-analysis will be published in a peer-reviewed journal.

3. **Conclusion**

This review protocol was used for a systematic review and meta-analysis to determine the effect of *Lycium barbarum L.* on plasma lipid concentrations. It clearly describes the type of trial, participants, interventions and results, as well as search strategies, data sources, extraction methods, and data analysis. Our search strategy will include both published and unpublished studies. Dyslipidemia, as an important risk factor of cardiovascular disease, has attracted wide attention in the world. Whether
*Lycium barbarum* L. has lipid-lowering effects will be verified in our systematic review and meta-analysis. We hope this study will provide evidence for the intervention of *Lycium barbarum* L. in lipid therapy and guide future research plans.

**Author contributions**

Conceptualization: Xueyuan Zeng, Jixiang Ren, Weimin Zhao  
Data curation: Xueyuan Zeng, Libo Xia, Junliang Wu  
Formal analysis: Xueyuan Zeng, Yunlong Xu, Chengwei Zhang  
Funding acquisition: Jixiang Ren  
Methodology: Xueyuan Zeng, Jixiang Ren  
Project administration: Weimin Zhao, Jixiang Ren  
Resources: Junliang Wu, Chengwei Zhang, Ziyou Tian  
Software: Xueyuan Zeng, Yunlong Xu  
Supervision: Jixiang Ren, Xueyuan Zeng  
Writing – original draft: Xueyuan Zeng  
Writing – review & editing: Xueyuan Zeng, Jixiang Ren, Weimin Zhao

**References**

[1] Kopin L, Lowenstein C. Dyslipidemia. Ann Intern Med 2017;167:ITC81–96.

[2] Mozaffarian D, Benjamin EJ, Go AS, et al. Writing Group Member-sExecutive summary: heart disease and stroke statistics—2016 update: a report from the american heart association. Circulation 2016;133:447–54.

[3] Ren J, Grundy SM, Liu J, et al. Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). Atherosclerosis 2010;211:327–32.

[4] Rodriguez-Colon SM, Mo J, Duan Y, et al. Metabolic syndrome clusters and the risk of incident stroke: the atherosclerosis risk in communities (ARIC) study. Stroke 2009;40:200–5.

[5] Armitage J. The safety of statins in clinical practice. Lancet 2007; 370:1781–90.

[6] Zeng Q, Li N, Pan XF, Chen L, Pan A. Clinical management and treatment of obesity in China [published correction appears in Lancet Diabetes Endocrinol. 2021 Jul;9(7):e2]. Lancet Diabetes Endocrinol 2021;9:393–405.

[7] Amagase H, Farvsworth NR. A review of botanical characteristics, phytochemistry, clinical relevance in efficacy and safety of *Lycium barbarum* fruit (Goji). Food Res Int 2011;44:1702–17.

[8] Wu D-T, Guo H, Lin S, et al. Review of the structural characterization, quality evaluation, and industrial application of *Lycium barbarum* polysaccharides. Trends Food Sci Technol 2018;79:171–83.

[9] Potterat O, Goij (Lycium barbarum and L. chinense): phytochemistry, pharmacology and safety in the perspective of traditional uses and recent popularity. Planta Med 2010;76:7–19.

[10] Wang H, Li J, Tao W, et al. Lycium ruthenicum studies: molecular biology, phytochemistry and pharmacology. Food Chem 2018;240:759–66.

[11] Zeng S, Liu Y, Wu M, et al. Identification and validation of reference genes for quantitative real-time PCR normalization and its applications in *lyceum*. PLoS One 2014;9:e97039.

[12] Wawruszak A, Czerwonka A, Okla K, Rzeski W. Anticancer effect of ethanol *Lycium barbarum* (Goji berry) extract on human breast cancer T47D cell line. Nat Prod Res 2015;30:1.

[13] Tang W-M, Chan E, Kwok C-Y, et al. A review of the anticancer and immunomodulatory effects of Lycium barbarum fruit. Inflammopharmacology 2012;20:307–14.

[14] Zhang Q, Chen W, Zhao J, Xi W. Functional constituents and antioxidant activities of eight Chinese native goji genotypes. Food Chem 2016;200:230–6.

[15] Tian X, Liang T, Liu Y, Ding G, Zhang F, Ma Z. Extraction, structural characterization, and biological functions of *lycium barbarum* polysaccharides: a review. Biomolecules 2019;9:389.

[16] Jin M, Huang Q, Zhao K, Shang P. Biological activities and potential health benefit effects of polysaccharides isolated from *Lycium barbarum* L. Int J Biol Macromol 2013;54:16–23.

[17] Luo Q, Cai Y, Yan J, Sun M, Corke H. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from *Lycium barbarum*. Life Sci 2004;76:137–49.

[18] de Souza Zanchet MZ, Nardi GM, de Oliveira Souza Bratti L, Filipin-Monteiro FB, Locatelli C. *Lycium barbarum* reduces abdominal fat and improves lipid profile and antioxidant status in patients with metabolic syndrome. Oxid Med Cell Longev 2017;2017:9763210.

[19] Paul Hsu CH, Nance DM, Amagase H. A meta-analysis of clinical improvements of general well-being by a standardized *Lycium barbarum*. J Med Food 2012;15:1006–14.

[20] Amagase H, Sun B, Nance DM. Immunomodulatory effects of a standardized *lycium barbarum* fruit juice in Chinese older healthy human subjects. J Med Food 2009;12:1159–65.

[21] Amagase H, Sun B, Borek C. *Lycium barbarum* (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults. Nutr Res 2009;29:19–25.

[22] Amagase H, Nance DM. A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized *Lycium barbarum* (goji) juice, GoChiTM. J Altern Complement Med 2008;14:403–12.

[23] Toh DWK, Xia X, Sutanto CN, et al. Enhancing the cardiovascular protective effects of a healthy dietary pattern with wolfberry (*Lycium barbarum*): a randomized controlled trial. Am J Clin Nutr 2021;114:80–9.

[24] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.